Novel dendrimer - biomedical material drug carrier

Dendritic polymers, known as the "fourth generation of new polymer materials", have attracted wide attention from the scientific community and industry. The novel features of the material are: highly branched molecular structure, a large number of surface functional groups, the presence of cavities within the molecule, the monodisperse molecular weight distribution, and the molecular size of nanometer. The structural characteristics of dendritic molecules make them have unique properties: excellent dissolution and dispersion properties, low melt viscosity and solution viscosity, not easy to crystallize, easy to form films, showing unparalleled nano characteristics.
Dendritic polymers have inherent advantages in the biomedical field due to their high efficiency in gene and drug delivery, solubilization of drug molecules, slow release effect brought by molecular cavities, high permeability and retention effect conferred by nano size, and highly repeatable molecular structure. It can be used in nanomedicine, targeted drug delivery, drug sustained release, gene expression, nuclear magnetic imaging and other fields. At present, this series of products has been used in the research of anti-cancer anti-inflammatory and anti-microbial drugs, most of which are in the experimental stage in vivo and in vitro.

Product performance
Dendritic polymer gives excellent properties:
• Nanoscale size;
• Have physical and chemical properties similar to proteins;
• Low cytotoxicity;
• Good biocompatibility;
• Increase the solubility and stability of the drug;
• Increase drug activity;
• Slow release and targeting of drugs.
Basic physical properties

Slow release effect of drug carrier
As an example, the complex of PAMAM and MTX in dendritic polymer series products was formed in different concentration of salt buffers, and the drug sustained release time was significantly prolonged. When PAMAM is not added as a drug carrier, the drug release time is close to complete release in 10 hours, while when PAMAM is added as a drug carrier, it is still not completely released in 70 hours, and 20% to 40% of the drug components are still retained, as shown in the figure below:


Applicable brands: CYD-D850, CYD-D418, CYD-D202, etc.